Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.

Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.

Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its...

Merakris Sponsored Study Opens Door to Precision-Based Approaches to Wound Healing RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- A recently published manuscript containing research sponsored, in part, by Merakris Therapeutics has opened the door to more...

Study Shows Effectiveness of Merakris’ Wound Care Products RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...